Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine MSP-1014 selected based on head-to-head comparison to psilocybin and its active metabolite psilocin MSP-1014 showed greater safety and efficacy in in vitro and in vivo preclinical models Cost...

Mindset Pharma Announces Promising Test Results of its Novel and Proprietary Psilocybin-Inspired Compounds TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mindset Pharma ("Mindset"), a leading drug discovery and development business focused on next-generation psychedelic medicines to treat neuropsychiatric...

Mindset Pharma Announces Filing of Groundbreaking Psilocybin Synthesis Patent TORONTO, July 27, 2020 (GLOBE NEWSWIRE) -- Mindset Pharma (“Mindset”), a leading drug discovery business focused on developing next-generation psychedelic medicines, announces today the filing of a...

North Sur Resources and Mindset Pharma Announce Proposed Transaction to Accelerate Development of Medical Psychedelics Industry VANCOUVER, British Columbia, June 29, 2020 (GLOBE NEWSWIRE) -- North Sur Resources Inc. (“North Sur”) and Mindset Pharma Inc. (“Mindset”) are pleased to announce that they have signed a binding...